AstraZeneca to share rights with J&J for abiraterone in Japan

10/11/2013 | Reuters

AstraZeneca and Johnson & Johnson agreed to jointly promote the latter's prostate cancer drug abiraterone in Japan. The drug, marketed as Zytiga in the U.S. and Europe, is under regulatory review in Japan.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC